Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Supersizes Its Order For LABA Safety Studies

This article was originally published in The Pink Sheet Daily

Executive Summary

The trials, which follow a label change and new REMS, will encompass seven times the patients included in the studies submitted to FDA for approval.

You may also be interested in...



Six Years And Four Trials Later, LABA/ICS Combos Twist Free Of Box Warning

US FDA concludes that combination products do not increase risk of serious asthma-related events compared to inhaled corticosteroids alone.

Breo Ellipta Stumbles On Pediatric Asthma Claim, But Advair Helps Break The Fall

FDA approves GlaxoSmithKline’s LABA/inhaled corticosteroid combo for asthma in adults but says more data needed in adolescents. GSK plans to throw additional promotional support behind the existing pediatric asthma claim for Advair, which is expected to face generic competition in the coming years.

Boehringer’s Striverdi Respimat Approved For COPD, But Without Exercise Claim

The long-acting beta agonist olodaterol cleared FDA for treatment of chronic obstructive pulmonary disease, but it didn’t gain the differentiating claim the German pharma was seeking.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel